Member News
-
Ucore’s Rare Earth Separation Commercial Demonstration Plant On-Track for Q4-2022 Commissioning
Ucore’s rare earth separation commercial demonstration plant is designed to process: Tens of tonnes of mixed rare earth…
-
Zentek Provides Update on HVAC Testing
September 15, 2022 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, reports,…
-
Awakn Life Sciences Reports Strong Q2 2022 Results
Awakn delivered revenue growth of 34% in Q2 Awakn also announces closing of first tranche of private placement…
-
Fjordland Concludes Exploration Program at South Voisey’s Bay
September 15, 2022 (Source) – Fjordland Exploration Inc. (TSXV: FEX) (the “Company”) announces that in conjunction with Ivanhoe Electric Inc.,…
-
dynaCERT to Exhibit at IAA Transportation 2022, the World’s Largest Platform for Transport and Logistics, to be held in Hanover, Germany from September 20th to 25th
September 15, 2022 (Source) – dynaCERT Inc. (TSX: DYA) (OTCQX: DYFSF) (FRA: DMJ) (“dynaCERT” or the “Company”) is pleased…
-
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
September 14, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (“Hemostemix” or the “Company”) is pleased to announce…
-
Hemostemix Announces Its Presentation to the Emerging Growth Conference
September 14, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) invites individuals,…
-
Murchison Intersects Best Hole to Date on HPM Property 121.2 metre Interval with a pXRF Estimate of 1.39% Ni Eq (or 4.14% Cu Eq) – Including 21.0 metre at 3.43% Ni Eq (or 10.25% Cu Eq)
September 14, 2022 (Source) – Murchison Minerals Ltd. (“Murchison” or the “Company”) (TSXV:MUR)(OTCQB:MURMF) is pleased to announce results analysed using portable…
-
Valeo Pharma Enters into Canadian Commercial Services Agreement with Veru for Sabizabulin in Hospitalized Adult Patients with Covid-19 at High Risk for Acute Respiratory Distress Syndrome (ARDS)
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo…
